Japan’s FY2024 pharmaceutical sales revealed a sharp divergence among immune checkpoint inhibitors as MSD’s Keytruda (pembrolizumab) surged toward the 200-billion-yen…
HOME > ORGANIZATION
ORGANIZATION
- JPMA to Draw Up Opinion on TPP During This Month
October 20, 2011
- Toray to Join JPMA in November
October 20, 2011
- The Number of Applicants Increases 779 to 5911 for MR Exam
October 20, 2011
- Keizai Doyukai’s Hasegawa Appointed National Strategy Council’s Private Sector Member, Vows “All-Out Effort
October 19, 2011
- JGA President Sawai Insists on Keeping 70% Rule for New Generics
October 19, 2011
- Vaccine Industry Must Continue to Present Proposals t oGov’t: Mr Fushimi of JAVI
October 18, 2011
- Dispensing Fees May Be Cut to Enable Hike in Medical Fees: Mr Urushibata of Chuikyo
October 18, 2011
- JPA Opposes TPP on Fears of Drug Safety
October 14, 2011
- Osteoporosis Foundation Survey Shows Patient Interest in Monthly BP Formulation
October 14, 2011
- CSMIC’s Kobayashi Questions Proposal to Freeze NHI Prices
October 12, 2011
- 17 Additional Products Eligible for PDSC Development Subsidies
October 12, 2011
- Industry to Seek Additional Data for Full Introduction of Premium for New Drug Development: Mr Negi
October 11, 2011
- OPMA to Develop Projects for Kansai Innovation Special area
October 11, 2011
- JACDS to Propose Reforms to Promote Switch-OTC Progress in Japan
October 11, 2011
- Association-managed Pharmacies Should Become “Home Healthcare Support Centers”: Mr Kodama of JPA
October 11, 2011
- JPA Announces FY2010 Results of Drug Event Monitoring for SU Drugs
October 11, 2011
- JPMA to Work with IFPMA to Tackle Non-communicable Diseases in Developing World
October 10, 2011
- Speed, Quality of Clinical Trials Have Increased: Mr Kawaguchi of JPMA
October 10, 2011
- Leading Biotech Clusters in Osaka, Munich Sign Partnership Agreement
October 5, 2011
- Permanent Introduction of Premium for New Drug Development Is an Option: Executive Director Miura of JPA
October 3, 2011
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…